angiotensinconvert
enzym
ace
play
pivot
role
reninangiotensin
system
ra
aceinhibitor
wide
use
sever
clinic
condit
includ
hypertens
heart
failur
recent
homologu
ace
ace
discov
ace
ace
emerg
key
enzym
ra
ace
may
play
role
neg
regul
ace
moreov
ace
appear
import
enzym
outsid
classic
ra
hydrolyz
apelin
dynorphin
desargbradykinin
peptid
substrat
precis
interplay
tissu
ace
ace
substrat
byproduct
present
still
unclear
aceinhibitor
reduc
angiotensin
ii
format
bradykinin
degrad
inhibit
ace
activ
moreov
aceinhibitor
differ
affin
tissu
ace
suggest
tissu
ace
affin
might
respons
benefici
properti
drug
aceinhibitor
also
increas
nitric
oxid
avail
activ
sever
kinas
may
regul
protein
synthesi
interact
nucleu
cell
outsidein
signal
outsidein
signal
may
also
activ
bradykinin
although
precis
signific
outsidein
signal
still
unclear
new
role
aceinhibitor
may
repres
discrimin
factor
versu
angiotensin
ii
receptor
antagonist
mini
review
summar
new
aspect
concern
recent
discov
biolog
function
ra
particular
ace
ace
aceinhibitor
cardiovascular
system
classic
concept
convers
angiotensin
vasoconstrictor
angiotensin
ii
ang
ii
well
degrad
potent
vasodil
bradykinin
catalyz
angiotensinconvert
enzym
ace
ectoenzym
particularli
abund
endotheli
surfac
lung
well
known
ace
play
pivot
role
reninangiotensin
system
ra
consequ
regul
blood
pressur
volum
homeostasi
vascular
function
cell
growth
investig
awar
ra
centuri
initi
discoveri
renin
tigerstedt
bergman
classic
ra
paradigm
renin
releas
juxtaglomerular
cell
kidney
circul
convert
angiotensinogen
liver
angiotensin
angiotensin
subsequ
hydrolyz
ace
lung
form
ang
ii
ace
potenti
hydrolyz
mani
protein
appreci
enzymat
process
angiotensin
ang
ii
cardiovascular
effect
extens
report
addit
ace
mediat
hydrolysi
bradykinin
typic
consid
blood
pressurelow
effect
bradykinin
may
also
act
regul
cardiac
function
interestingli
ace
readili
hydrolyz
bradykinin
angiotensin
therefor
net
physiolog
effect
ace
increas
product
vasoconstrictor
decreas
avail
vasodil
involv
endotheli
factor
nitric
oxid
endotheli
deriv
hyperpolar
factor
produc
consequ
bradykinin
receptor
activ
may
also
consid
last
decad
becom
increasingli
appar
despit
provid
initi
benefit
hemodynam
support
continu
ra
activ
may
contribut
progress
worsen
diseas
heart
failur
respect
find
ace
tissu
ace
primarili
local
variou
tissu
organ
within
endothelia
parenchyma
well
inflammatori
cell
gain
pathophysiolog
import
consid
rapid
progress
understand
molecular
physiolog
ra
mani
complex
surpris
detail
would
continu
emerg
unexpect
howev
year
research
major
new
concept
would
surfac
requir
scientist
clinician
rethink
system
role
cardiovascular
regul
recent
discov
distinct
isoform
ace
express
human
found
almost
exclus
testi
tace
recent
two
major
conceptu
chang
would
consid
regard
ra
ace
aceinhibitor
cardiovascular
system
first
surpris
discoveri
occur
discoveri
ace
aceh
may
produc
factor
vasodil
properti
second
new
concept
discov
ingrid
fleme
group
term
outsidein
signal
author
mechan
bradykinin
aceinhibitor
activ
sever
kinas
may
regul
protein
synthesi
review
two
new
concept
date
section
tissu
ace
cardiac
hypertrophi
consid
emphasi
given
organ
protect
aceinhibitor
said
physiolog
condit
high
level
tissu
ace
found
capillari
bed
lung
consid
integr
part
classic
ra
hand
tissu
site
includ
heart
express
rel
low
level
ace
least
physiolog
condit
within
normal
heart
densiti
ace
right
atrium
higher
left
atrium
ventricl
larger
part
tissu
ace
found
endothelium
larg
small
coronari
arteri
arteriol
immunohistochem
analysi
reveal
half
capillari
immunoreact
ace
coronari
venou
vessel
almost
complet
devoid
enzym
site
cardiac
tissu
ace
express
includ
endocardi
layer
cardiac
valv
littl
ace
found
normal
adult
cardiomyocyt
situ
patholog
activ
local
ra
includ
tissu
ace
sever
deleteri
effect
cardiovascular
function
tissu
ace
play
critic
role
endotheli
function
direct
pleiotrop
action
ang
ii
also
bradykinindepend
mechan
tissu
ace
larg
local
endothelium
endotheli
dysfunct
often
associ
activ
tissu
ace
activ
disrupt
balanc
vasodilat
vasoconstrict
moreov
vascular
smooth
muscl
cell
growth
inflammatori
oxid
state
vessel
wall
alter
fig
endotheli
dysfunct
occur
respons
number
risk
factor
injuri
ischemiareperfus
hypertens
diabet
mellitu
hypercholesteremia
cigarett
smoke
ang
ii
produc
activ
endotheli
ace
impair
nitric
oxid
bioactiv
mainli
oxid
stress
ang
iiinduc
product
superoxid
radic
scaveng
nitric
oxid
reduc
endotheliumdepend
vasodilat
action
independ
effect
ace
degrad
bradykinin
modul
endothelialdepend
vasodil
respons
activ
b
receptor
evid
ace
express
increas
atherosclerosi
ang
ii
may
contribut
diseas
progress
increas
oxid
stress
chemoattract
adhes
molecul
express
lead
inflamm
ang
ii
also
favor
prolif
inflammatori
prothrombot
action
fig
fact
substanti
evid
atherosclerosi
plaqu
repres
import
target
ace
inhibitor
action
see
yet
ace
upregul
risk
factor
restrict
vasculatur
myocyt
fibroblast
also
recruit
ace
express
injur
heart
moreov
macrophag
invad
injur
myocardium
bring
high
level
ace
activ
interstiti
site
ang
ii
accumul
mast
cell
cardiac
tissu
also
sourc
ang
ii
action
chymas
fig
tissu
ace
upregul
describ
virtual
model
cardiac
injuri
includ
hypertrophi
pressur
volumeoverload
myocardi
infarct
heart
failur
elev
enzym
level
found
exclus
affect
ventricl
elev
wall
stress
believ
critic
factor
cardiac
ace
induct
notabl
unstress
cardiomyocyt
cell
cultur
report
express
ace
cardiomyocyt
thu
abl
gener
ang
ii
local
especi
respons
mechan
stretch
increas
local
format
ang
ii
increas
bradykinin
degrad
favor
unbalanc
effect
may
favor
cardiovascular
diseas
progress
wherea
cardiac
ace
increas
fail
heart
pulmonari
ace
decreas
pulmonari
congest
complic
condit
oppos
regulatori
step
may
protect
angiotensin
conversiondegrad
lung
increas
ace
substrat
heart
inde
aceinhibitor
effect
reduc
system
high
blood
pressur
aggrav
pulmonari
congest
exert
organprotect
action
increasingli
appar
contribut
tissu
ace
ang
ii
concert
sever
factor
develop
mainten
left
ventricular
hypertrophi
fig
angiotensin
ii
type
receptor
rs
also
upregul
experiment
induc
cardiac
hypertrophi
ang
ii
shown
caus
hypertrophi
direct
action
cardiomyocyt
pinto
et
al
ohmichi
et
al
found
patholog
remodel
earli
myocardi
infarct
occur
predominantli
subject
ace
dd
genotyp
observ
author
attract
attent
ace
gene
polymorph
howev
genotyp
consist
associ
hypertens
preval
extent
coronari
arteri
diseas
myocardi
infarct
thu
role
genet
variabl
ace
remain
fulli
elucid
discuss
cardiac
pressurevolum
overload
lead
hypertrophi
tissu
ace
major
player
even
rstimul
ang
ii
isol
cardiomyocyt
lead
induct
characterist
hypertroph
phenotyp
includ
protein
synthesi
cell
growth
reexpress
fetal
gene
programm
absenc
prolifer
great
number
intracellular
signal
pathway
involv
hypertroph
respons
character
last
decad
involv
molecul
oper
isol
particip
orchestr
respons
gener
interdepend
crosstalk
network
explain
fact
mechan
involv
cardiac
hypertrophi
still
complet
clear
eg
sever
pathway
ang
ii
link
growth
regul
cardiac
cell
describ
among
transactiv
differ
receptor
system
seem
play
pivot
role
fig
hypertroph
effect
ang
ii
cardiac
noncardiac
cell
delay
requir
hour
day
appear
involv
sequenti
parallel
activ
varieti
protein
kinas
normal
associ
signal
pathway
downstream
tyrosin
kinas
receptor
kinas
typic
implic
mediat
cardiac
growth
includ
mitogenactiv
protein
kinas
mapk
extracellular
signalregul
kinas
phosphatidylinositol
depend
signal
kinas
protein
kinas
b
pkbakt
kinas
axi
activ
pathway
readili
explain
classic
g
proteincoupl
receptor
gpcr
signal
exampl
protein
kinas
c
pkc
depend
activ
yet
mobil
addit
growthdepend
kinas
r
difficult
elucid
first
evid
gpcrmediat
transactiv
epiderm
growth
factor
receptor
egfr
lack
intrins
tyrosin
kinas
activ
provid
daub
et
al
thu
potenti
explain
prolifer
trigger
nonclass
gpcr
signal
studi
support
idea
r
activ
ang
ii
start
cascad
lead
cardiac
hypertrophi
fig
propos
pathway
start
rdepend
transactiv
egfr
cardiomyocyt
may
involv
stimul
membranebound
metalloproteas
mmp
turn
cleav
egfr
ligand
heparinbind
egf
hbegf
plasma
membraneassoci
precursor
prohbegf
mechan
r
activ
mmp
unclear
may
fig
schemat
diagram
depict
signal
cascad
activ
classic
g
proteincoupl
receptor
gpcr
activ
side
longterm
gcrpmediat
hypertrophi
side
b
classic
r
signal
side
respons
acut
ang
ii
action
vasoconstrict
occur
via
g
protein
g
lead
activ
phospholipas
pcb
subsequ
gener
second
messeng
diacylglycerol
dag
inositol
trisphosph
turn
stimul
protein
kinas
c
pkc
mobil
intracellular
calcium
side
b
start
dash
arrow
depict
longterm
gcrpmediat
hypertrophi
process
may
depend
upon
egfr
transactiv
term
tripl
membranepass
signal
tmp
tmp
attribut
intracellular
signal
mechan
epiderm
growth
factor
receptor
egfr
transactiv
requir
matrix
metalloproteas
mmp
depend
extracellular
cleavag
proheparinbind
egf
prohbegf
liber
solubl
hbegf
may
activ
egfr
follow
activ
sever
intracellular
kinas
activ
may
play
pivot
role
regul
cellular
growth
prolifer
classic
gpcr
signal
via
pkcactiv
also
concur
activ
adam
disintegrin
metalloproteinas
inhibitor
metalloenzym
acronym
see
also
text
involv
ca
tyrosin
kinas
src
prolinerich
tyrosin
kinas
subsequ
activ
egfr
lead
mobil
signal
pathway
includ
akt
kinas
fig
kinas
may
play
pivot
role
regul
cellular
growth
prolifer
via
increas
translat
effici
capac
final
must
kept
mind
hypertroph
effect
ang
ii
well
adrenalin
seen
mediat
increas
product
sever
endogen
factor
includ
endothelin
et
fibroblast
growth
factor
fgf
fig
instanc
ang
ii
upregul
endothelin
convert
increas
level
precursor
et
prepropeptid
absenc
fgf
hypertens
evok
ang
ii
induc
cardiac
hypertrophi
due
crosstalk
ang
ii
contribut
cardiac
hypertrophi
atheroscleros
plaqu
attempt
done
use
endothelin
receptor
blocker
treatment
cardiovascular
diseas
spite
benefici
effect
obtain
pulmonari
hypertens
conflict
result
obtain
congest
heart
failur
particular
term
event
reduct
heart
failur
antihypertens
treatment
aim
reduc
blood
pressur
suffici
due
present
state
art
doubt
aceinhibitor
firstlin
antihypertens
substanc
due
vascular
myocardi
protect
effect
side
effect
well
known
ace
inhibit
decreas
risk
myocardi
infarct
way
may
independ
abil
decreas
blood
pressur
recent
metaanalysi
four
clinic
trial
confirm
ace
inhibitor
administr
also
benefici
acut
myocardi
infarct
treatment
even
two
trial
among
includ
metaanalysi
cooper
new
scandinavian
enalapril
surviv
studi
ii
third
subanalysi
italian
group
studi
streptokinas
myocardi
infarct
gissi
queri
benefici
effect
aceinhibitor
earli
phase
acut
myocardi
infarct
possibl
explan
doubt
benefit
resid
fact
earli
phase
increas
level
bradykinin
vasodil
cardiodepressor
may
appropri
europa
hope
trial
also
well
plan
well
execut
studi
show
benefici
effect
aceinhibitor
secondari
prevent
cardiovascular
event
patient
coronari
heart
diseas
unfortun
two
studi
present
directli
compar
nevertheless
studi
learn
mani
thing
aceinhibitor
organ
protector
confirm
princip
target
ace
inhibitor
action
tissu
site
also
learn
concentr
aceinhibitor
past
consid
rel
high
dose
inde
adequ
dose
heart
failur
earli
associ
aceinhibitor
also
emerg
adequ
strategi
human
anim
aceinhibitor
r
antagonist
shown
prevent
regress
develop
hypertrophi
underli
mechan
cardiovascular
remodel
relev
therapi
aim
counteract
mechan
recent
review
particular
aceinhibitor
aldosteron
antagonist
proven
effect
modul
process
remodel
reduc
occurr
advers
event
heart
failur
pharmacokinet
properti
variou
aceinhibitor
indic
differ
bind
characterist
tissu
ace
tissu
ace
thought
increas
inflamm
vasoconstrict
thought
promot
vascular
remodel
plaqu
stabil
decreas
myocardi
infarct
occurr
ace
inhibit
treatment
attribut
inhibit
local
tissu
ace
vasculatur
howev
recent
studi
examin
question
found
correl
tissu
ace
affin
risk
first
nonfat
myocardi
infarct
hypertens
patient
studi
aceinhibitor
categor
group
base
rel
affin
tissu
ace
higheraffin
tissu
aceinhibitor
consist
quinapril
benazepril
ramipril
loweraffin
tissu
aceinhibitor
consist
lisinopril
enalapril
fosinopril
captopril
nevertheless
univers
definit
literatur
constitut
tissueac
inhibitor
undoubtedli
compar
experiment
clinic
studi
address
signific
drug
differ
impact
clinic
event
whatev
outcom
studi
increas
capac
manag
highli
benefici
tool
ace
homologu
ace
capabl
produc
angiotensin
peptid
may
vasodil
properti
signific
differ
ace
ace
gene
ace
gene
give
rise
two
isoform
somat
ace
tace
singl
ace
protein
speci
appear
form
human
somat
ace
resid
chromosom
chromosom
mous
rat
respect
consist
exon
germin
tace
express
test
aris
promot
locat
within
intron
downstream
gene
duplic
make
protein
singl
domain
catalyt
site
ace
gene
locat
region
x
chromosom
human
mice
rodent
map
quantit
trait
loci
qtl
hypertens
rat
human
ace
gene
highli
express
endothelium
heart
tubular
epithelia
kidney
gastrointestin
tract
mice
ace
also
observ
lung
importantli
human
two
singl
nucleotid
polymorph
ace
qtl
associ
cardiovascular
diseas
ace
although
structur
similar
ace
differ
catalyt
profil
ace
act
dipeptidylpeptidas
gener
ang
ii
angiotensin
trough
remov
ctermin
dipeptid
hisleu
ace
carboxypeptidas
catalys
convers
vasoconstrictor
ang
ii
ang
remov
carboxytermin
amino
acid
phenylalanin
moreov
ace
cleav
ctermin
aminoacid
angiotensin
nonapeptid
ang
may
convert
ang
ace
fig
tabl
biolog
function
ang
ang
still
poor
understood
ang
may
potenti
ang
iiinduc
vasoconstrict
ang
may
play
import
role
regul
cardiovascular
function
ang
serv
substrat
ace
form
ang
ii
known
act
vasoconstrictor
prohypertroph
factor
angiotensin
also
metabol
ace
form
ang
action
still
well
understood
start
either
ang
ii
ang
ace
catalyz
product
ang
oppos
effect
ang
ii
via
interact
ma
ang
receptor
appear
ace
ace
duce
vasodilat
apoptosi
growth
arrest
basi
ace
express
physiolog
role
substrat
suggest
ace
may
act
tissuespecif
neg
feedback
regul
activ
ra
thu
ace
ace
may
ultim
oppos
physiolog
effect
contrast
ace
ace
hydrolyz
bradykinin
inhibit
typic
aceinhibitor
accept
neither
ace
angiotensin
defici
mice
exhibit
defect
heart
develop
suscept
heart
diseas
recent
studi
ace
knockout
mice
report
appar
conflict
result
import
enzym
cardiovascular
function
reduct
ace
level
would
lead
reduc
degrad
vasoconstrictor
reduc
format
vasodil
thu
favor
blood
pressur
increas
fact
line
mice
lack
ace
gene
allr
et
al
report
elev
level
baselin
blood
pressur
last
report
seem
also
agreement
observ
reduc
ace
level
sever
rat
model
hypertens
sabra
hypertensivepron
strain
sbhi
spontan
hypertens
rat
shr
spontan
hypertens
strokepron
rat
shrsp
howev
also
report
ace
defici
mice
show
reduct
heart
contractil
signific
decreas
blood
arteri
ventricular
pressur
awak
anesthet
anim
compar
litterm
control
possibl
reunif
appar
conflict
result
ace
knockout
mice
may
deriv
fact
reduct
blood
pressur
accompani
impair
heart
function
may
thu
argu
ace
knockout
mice
initi
excess
uncontrast
ang
iimedi
effect
occur
lead
increas
vascular
tone
pressur
long
last
ang
ii
action
sustain
patholog
cell
growth
lead
impair
cardiac
function
resembl
sort
cardiac
stunninghibern
observ
murphi
et
al
thu
heart
stun
may
respons
reduct
blood
pressur
intrigu
ace
knockout
mous
ablat
ace
express
abolish
cardiac
dysfunct
phenotyp
mous
observ
doubl
mutant
mous
aceac
knockout
mous
display
normal
cardiac
function
support
idea
unoppos
effect
ang
ii
may
account
cardiac
dysfunct
singl
ace
knockout
mous
also
propos
ace
function
may
limit
ra
fact
ace
cleav
ctermin
residu
sever
peptid
apelin
ghrelin
desarg
bradykinin
neurotensin
dynorphyn
physiolog
function
ace
substrat
well
function
form
product
summar
tabl
minireview
emerg
role
apelin
cardiovascular
system
extens
review
crosstalk
ra
peptid
exist
two
form
apelin
recent
identifi
endogen
ligand
human
apj
orphan
receptor
homolog
r
apelin
display
diuret
effect
found
supraott
nucleu
hypothalamu
seem
inhibit
electr
activ
vasopressinreleas
neuron
apelin
exert
also
nitric
oxidedepend
vasodil
posit
inotrop
activ
apjdefici
anim
ang
ii
hypertens
respons
result
enhanc
thu
suggest
spite
similar
rs
apjreceptor
activ
latter
may
counteract
pressor
effect
activ
former
receptor
also
propos
ang
ii
may
induc
releas
apelin
vascular
endotheli
cell
posit
inotrop
activ
apelin
demonstr
isol
prepar
intact
anim
relat
pkc
activ
consequ
na
h
exchang
phosphorylationactiv
result
increas
intracellular
na
concentr
activ
ca
na
exchang
lead
increas
intracellular
ca
concentr
thu
favor
increas
contractil
propos
due
properti
apelin
could
therapeut
use
heart
failur
although
report
two
week
apelintreat
sign
hypertrophi
appear
longterm
studi
aim
ascertain
whether
apelin
may
induc
hypertrophi
requir
said
ace
inhibit
aceinhibitor
recent
novel
ace
peptid
inhibitor
describ
use
ace
antagonist
use
elucid
ace
function
vivo
final
ace
uniqu
among
mammalian
carboxypeptidas
contain
hexxh
zinc
motif
resembl
bacteri
enzym
thermu
aquaticu
taq
carboxypeptidas
function
receptor
sar
coronaviru
new
concept
discov
ingrid
fleme
group
use
human
umbil
vein
endotheli
cell
porcin
aortic
endotheli
cell
stabli
transfect
human
somat
ace
model
fleme
cowork
demonstr
ramiprilat
perindoprilat
increas
casein
kinas
mediat
phosphoryl
ace
ser
coimmunoprecipit
studi
reveal
ace
associ
inhibitor
increas
aceassoci
activ
interestingli
bradykinin
angiotensin
increas
ace
ser
phosphoryl
activ
suggest
natur
occur
signal
transduct
pathway
bradykinin
requir
classic
receptor
exist
importantli
possibl
phosphoryl
result
crosstalk
signal
transduct
pathway
rule
control
experi
use
porcin
endotheli
cell
r
bradykinin
b
receptor
subsequ
two
aceassoci
protein
cjun
ntermin
kinas
jnk
map
kinas
kinas
identifi
addit
fig
author
report
associ
protein
ace
also
provid
convinc
evid
aceassoci
jnk
activ
increas
cell
treat
aceinhibitor
bradykinin
interestingli
jnk
activ
bind
ace
depend
phosphoryl
ace
ser
activ
jnk
ramiprilat
result
accumul
phosphoryl
cjun
nucleu
report
activ
transcript
ace
ace
increas
respons
ramiprilat
via
mechan
depend
jnk
activ
human
umbil
vein
endotheli
cell
cultur
mous
lung
vivo
word
fleme
cowork
clearli
demonstr
bind
ace
inhibitor
ace
result
activ
jnk
well
phosphoryl
cjun
transloc
nucleu
signal
pathway
therefor
like
affect
express
sever
protein
particular
express
ace
recent
lung
mice
primari
cultur
human
endotheli
cell
fleme
group
show
ramiprilatinduc
acedepend
increas
express
promot
activ
prevent
inhibit
jnk
author
suggest
ace
signal
cascad
involv
phosphoryl
ace
ser
consequ
ac
tivat
jnk
activ
explain
enhanc
product
prostacyclin
welldocu
consequ
ace
inhibitori
therapi
importantli
author
abl
demonstr
signal
pathway
initi
aceinhibitor
cell
cultur
also
activ
whole
anim
suggest
intracellular
signal
term
outsidein
signal
author
mediat
aceinhibitor
bradykinin
may
import
physiolog
mechan
author
suggest
ace
ad
class
socal
nonreceptor
cell
surfac
protein
identif
ace
signal
molecul
activ
bind
aceinhibitor
may
account
benefici
effect
drug
cardiovascular
system
cours
understand
full
spectrum
physiolog
event
initi
ace
outsidein
signal
requir
addit
studi
summari
evid
import
effect
ang
ii
independ
classic
g
protein
coupl
counterbalanc
role
ace
ace
ra
suggest
system
clearli
oper
physiolog
level
far
beyond
simpl
regul
vascular
tone
bodi
fluid
homeostasi
remark
short
period
time
mani
new
concept
accumul
role
tissu
ace
atr
organ
hypertrophi
reveal
new
aspect
includ
receptor
mediat
endocytosi
tyrosin
phosphoryl
signal
map
kinas
activ
transactiv
egfr
ace
substrat
involv
feedback
regul
ra
also
extrara
system
fact
ace
catalyz
convers
opiod
apelin
peptid
also
intrigu
outsidein
signal
bradykinin
old
substrat
may
play
new
role
gene
regul
act
ace
new
concept
particular
outsidein
signal
deviat
origin
one
aceinhibitor
consid
import
reduc
ang
ii
level
aceinhibitor
may
mimic
new
effect
bradykinin
clarif
physiolog
role
ace
outsidein
signal
apelin
may
hope
lead
develop
new
therapeut
heart
failur
hypertens
recent
structur
solut
ace
ace
could
facilit
futur
design
specif
drug
differ
affin
argu
therapeut
point
view
new
concept
taken
account
choos
ace
inhibitor
ang
ii
receptor
antagonist
cours
compar
experiment
clinic
studi
must
address
topic
light
new
concept
surpris
rapidli
evolv
field
new
concept
emerg
next
futur
